In France, [68Ga]Ga-PSMA-11 is a radiopharmaceutical drug available through compassionate access for patients with biologically recurrent prostate cancer, defined as a re-increase in serum prostate specific antigen (PSA) concentration [3]. The gene discussed is KLK3; the disease is prostate cancer.